Cco Astro 2011

Front 1

sakk 10/94 III RT+- cis

Back 1

ništa posebno, završena studija, statistički nejaka, sa cis 1 i 5 tj zračenja 20 mg, sa jedanikm oos ali css 55/43%.

Front 2

uloga hpv p16 proteina u HNC

Back 2

jači prognostički od stadija u orofarinksu i vjerojatno larinksu.

Front 3

HPV

Back 3

pozitivan pronostički čimbenik orofarinska 3yos - 82/57

Front 4

In the setting of non-small-cell lung cancer (NSCLC), stereotactic body radiation therapy (SBRT)

Back 4

high local control rates and improve survival vs conventionally fractionated radiotherapy in patients with medically inoperable stage I disease, 54 Gy (18 Gy in 3 fractions), 87.2%—only 2 patients experienced regional failure, and more than one half remained alive at 3 years

Front 5

phase II JCOG-0403 SBRT

Back 5

for operable T2N0M0 NSCLC, the 3-year overall survival rate following 48 Gy of radiation was 76.0%

Front 6

RTOG 9601 phase III trial of long-term androgen-deprivation therapy (ADT) with radiotherapy in patients with prostate cancer

Back 6

whether 2 years of androgen deprivation benefits those patients for whom post–radical prostatectomy radiotherapy is considered necessary due to an elevated prostate-specific antigen (PSA) level. Results showed a statistically significant improvement in freedom from disease progression and fewer distant metastases for ADT plus radiation compared to radiotherapy alone

Front 7

radioterapija kod LA prostate

Back 7

da uz ADT ima dodatni učinak, a RT treba provesti bez čekanja EORT 22911, da bi bilo koristi na OS od zračenja

Front 8

drugi pronostički markeri za prostatu

Back 8

Prognostic biomarkers under investigation in this setting include interleukin-6, chromogranin-A, E-cadherin, β-catenin, and many more

Front 9

phase III BC2001 study

Back 9

which was designed to determine whether the use of chemoradiotherapy improves local control vs radiotherapy alone and whether reducing the bladder area that receives a full radiotherapy dose can reduce late toxicity without compromising tumor control.
apliciran je 5fu s mitiomcinom i na smanjeni volumen prostate, sa boljim rezultatima

Front 10

kt za mm

Back 10

pakli/cis, 5fu/cis, 5fu/mitomicin, trastuzumab, gem

Front 11

tme + RT

Back 11

Subgroup analyses showed that radiotherapy was effective only in those patients with a negative circumferential resection margin (CRM), who have TNM stage III disease, or who have a tumor height above 5 cm

Front 12

rtog 9704 adj CRT u PCA

Back 12

U adj th treba gem, pa 5fu/RT, a ca19-9 manji od 90 (20vs9mj) što je potvrdilo CONKO-1

Front 13

GBM out of field reccurence % ?

Back 13

32 % !

Front 14

folfox + panitumumab

Back 14

negativan efekt za kras mutante, za razliku od folfirija i panitumumaba.

Front 15

%KRAS mutanata i koji kodon u mCRC

Back 15

40%, kodon 12 i 13, a za mutante 13 cetux ima slični učinak kao i za WT

Front 16

veliparib

Back 16

PARP functions as a key DNA-repair enzyme and has been shown to impart resistance of cancer cells to chemotherapy and radiation.[20] Inhibitors of PARP cause a failure of DNA-repair pathways, including base excision repair and single-strand break repair, ultimately leading to arrest of the replication fork, degeneration into double-strand breaks, and cell death

Front 17

rilotumumab

Back 17

Rilotumumab prevents hepatocyte growth factor binding to the c-Met receptor on the surface of tumor cells; therefore, it is a ligand-targeted agent. The results of this study suggest that the hepatocyte growth factor/c-Met signaling pathway may be a useful target in mCRC treatment

Front 18

temozolomid i veliparib u rezistentnom mCRC-u

Back 18

os 6 mj, pr 5%

Front 19

Aflibercept

Back 19

VEGF trap, a fusion protein that can bind VEGF-A, VEGF-B, and placental growth factor to inhibit angiogenesis. This agent is currently under investigation in the randomized phase III VELOUR study comparing FOLFIRI with vs without aflibercept for the second-line treatment of mCRC

Front 20

Perifosine

Back 20

oral PI3 kinase and AKT inhibitor that is being assessed in combination with capecitabine in a randomized phase III trial

Front 21

Regorafenib - studija CORRECT

Back 21

Regorafenib (also known as BAY 73-4506) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition